Thrombus Imaging with a Technetium-99m-Labeled, Activated Platelet Receptor-Binding Peptide

Journal of Nuclear Medicine

Volumn 37, Issue 5, 1996, Pages 775-781

  Lister James, John ^a   Knight, Linda C ^b   Maurer, Alan H ^b   Bush, Larry R ^b   Moyer, Brian R ^b   Dean, Richard T ^b  

^a BAYER PHARMA AG   (Germany)

^b NONE

Author keywords

Activated platelet imaging; Deep vein thrombosis; GPllb llla receptor; Technetium 99m labeled peptide; Thrombosis imaging

Indexed keywords

CYCLOPEPTIDE; DIAGNOSTIC AGENT; FIBRINOGEN RECEPTOR; TECHNETIUM COMPLEX; TECHNETIUM TC 99M P280;

ANIMAL; ARTICLE; DOG; DRUG EFFECT; HUMAN; ISOTOPE LABELING; METABOLISM; RABBIT; RAT; SCINTISCANNING; SPRAGUE DAWLEY RAT; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOPHLEBITIS; TISSUE DISTRIBUTION;

ANIMALS; BLOOD PLATELETS; DOGS; HUMANS; ISOTOPE LABELING; ORGANOTECHNETIUM COMPOUNDS; PEPTIDES, CYCLIC; PLATELET AGGREGATION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; THROMBOPHLEBITIS; TISSUE DISTRIBUTION;

EID: 0030138052     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. REFERENCES 1. Anderson FA, Wheeler HB, Goldberg RT, et al. A population-based perspective of the hospital incidence and case facility rates of deep vein thrombosis and pulmonary embolism. Ann intern Med l991;151:933-938.
2. Hull RD, Hirsh J, Carter CJ, et al. Pulmonary angiography, ventilation lung scanning and venography for clinically suspected pulmonary embolism with abnormal perfusion lung scan. Ann Intern Med 1983;98:891-899.
3. Rose SC, Zwiebel WJ, Nelson BD, et al. Symptomatic lower extremity deep venous thrombosis: accuracy, limitations and role of color duplex How imaging in diagnosis. Radiology 1990;175:639-644.
4. Davidson BL, Eilliott CG, Lensing AWA. Low accuracy of color Doppler ultrasound in the detection of proximal leg vein thrombosis in asymptomatic high-risk patients. Ann Intern Med 1992;117:735-738.
5. Som P, Oster ZH. Thrombus-specific imaging: approaching the elusive goal. J Nucl Med 1994;35:202-203.
6. Knight LC. Radiopharmaceuticals for thrombus detection. Semin Nucl Med 1990;20:52-67.
7. Koblik PD, De Nardo GL, Berger HJ. Current status of immunoscintigraphy in the detection of thrombosis and thromboembolism. Semin Nucl Med 1989;19:22l-237.
8. Kieffer N, Phillips DR. Platelet membrane glycoproteins: functions in cellular interactions. Ann Rev Cell Biol 1990;6:329-357.
9. Hawiger J. Adhesive interactions of blood cells and the vessel wall. In: Coleman R, Hirsh J, Marder V, Salzman E, eds. Hemostasis and thrombosis. Basic principles and clinical practice, 2nd ed. Philadelphia: JB Lippincott Co.; 1987;182-209.
10. JS Bennett, G Vilaire. Exposure of platelet fibrinogen receptors by ADP and cpinephrine. J Clin Invest 1979;64:1393-1401.
11. Ruggeri ZM, Houghten RA, Russell SR, Zimmerman TS. Inhibition of platelet function with synthetic peptides designed to be high-affinity antagonists of fibrinogen binding to platelets. Proc Natl Acad Sci USA 1986;83:5708-5712.
12. Knight LC, RadclifTe R, Maurer AH, Rodwell JD, Alvarez VL. Thrombus imaging with technetiurn-99m synthetic peptides based upon the binding domain of a monoclonal antibody to activated platelets. J Nucl Med 1994;35:282-288.
13. 99mTc-labeled 17 amino acid peptide (CYT-379). Nucl Med Biol 1994;21:131-142.
14. Zucker MB. Platelet aggregation measured by the photometric method. Meth Enzymol 1989;169:117-133.
15. Barker PL, Bullens S, Bunting S, et al. Cyclic RGD peptide analogues as antiplatelet antithrombotics. J Med Chem 1992;35:2040-2048.
16. Burnier JP, Gadek T, McDowell R. Platelet aggregation inhibitors having high specificity for GPIIb/IIIa. Int Pat Appl Pub No. WO 92/17492; Geneva, Switzerland: 1992.
17. 99mTc-antifibrin Fab' fragments for imaging venous thrombi: evaluation in a canine model. Radiology 1989;173:163-169.
18. Knight LC, Abrams MJ, Schwartz DA, Hauser MM, Kollman M, Gaul FE, Rauh DA. Preparation and preliminary evaluation of technetium-99m-labeled Fragment E, for thrombus imaging. J Nucl Med 1992;33:710-715.
19. Becker W, Borner W, Borst U. Technetium-99m-hexamethylpropyleneamineoxime (HMPAO) as a platelet label: evaluation of labeling parameters and first in vivo results. Nucl Med Commun 1988;9:83l-842.
20. Freiman DG. The structure of thrombi. In: Coleman R, Hirsh J, Marder V, Salzman E, eds. Hemostasis and thrombosis. Basic principles and clinical practice, 2nd ed. Philadelphia: JB Lippincott Co.; 1987;1123-1135.
21. Coller BS. Activation affects access to the platelet receptor for adhesive glycoproteins. J Cell Biol 1986;103:451-456.
22. Plow EF, Pierschbacher MD, Ruoslahti E, Marguerie GA, Ginsberg MH. The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets. Proc Natl Acad Sci USA 1985;82:8057-8061.
23. Samanen J, Ali F, Romoff T, et al. Development of a small ROD peptide fibrinogen receptor antagonist with potent antiaggregatory activity in vitro. J Med Chem 1991;34:3114-3125.
24. Alig L, Edenhofter A, Hadvary P, et al. Low molecular weight, nonpeptide fibrinogen receptor antagonists, J Med Chem 1992;35:4393-4407.
25. Zablocki JA, Miyano M, Garland RB, et al. Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp-Phe sequence of fibrinogen. A proposal on the nature of the binding interaction between the Arg-guanidine of RGDX mimetics and the platelet GP IIb/IIIa receptor. J Med Chem 1993;36:1811-1819.
26. Cook NS, Bruttger O, Pally C, Hagenbach A. The effects of two synthetic glycoprotein IIb/IIIa antagonists. Ro 43-8857 and L-700,462, on platelet aggregation and bleeding in guinea pigs and dogs: evidence that Ro 43-8857 is orally active. Throm Haemostasis 1993;70:838-847.
27. Ramjit DR, Lynch JJ, Sitko GR, et al. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis. J Pharmacol Exp Ther 1993;266:1501-1511.
28. Scarborough RM, Naughton A, Teng W, et al. Design of potent and specific integrin antagonists. J Biol Chem 1993;268:1066-1073.
29. 3 antagonists. J Med Chem 1994;37:l-9.
30. Mousa SA, Bozarth JM, Forsythe MS, et al. Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist. Circulation 1994;89:3-12.
31. Dennis MS, Henzel WJ, Pitti RM, et al. Platelet glycoprotein IIb/IIIa protein antagonists from snake venoms: evidence for a family of platelet-aggregation inhibitors. Proc Natl Acad Sci USA 1989;87:2471-2475.
32. Charo IF, Kieffer N, Phillips DR. Platelet membrane glycoproteins. In: Coleman R, Hirsh J, Marder V, Salzman E, eds. Hemostasis and thrombosis. Basic principles and clinical Practice, 3rd ed. Philadelphia: JB Lippincott Co.; 1994;489-507.
33. Muto P, Lastoria S, Varrella P, Vergara E, Bernardy JD, Borer JS, Salvatore M. Detection of deep venous thrombosis by technetium-99m-labeled synthetic peptides P-280: preliminary results. J Nucl Med 1994;34:80P.
34. Muto P, Lastoria S, Varrella P, et al. Detection of deep venous thrombosis with technetium-99m-labeled synthetic peptide P280. J Nucl Med 1995;36:1384-1391.